NCT03239210View on ClinicalTrials.gov

Effects of Ondansetron in Obsessive-compulsive and Tic Disorders

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions
Obsessive-Compulsive DisorderTic DisordersTourette Syndrome
Interventions
DRUG

Ondansetron

5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting

DRUG

Placebo

placebo equivalent

Trial Locations (2)

10016

New York University School of Medicine, New York

10962

The Nathan S. Kline Institute for Psychiatric Research, New York

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

NYU Langone Health

OTHER

NCT03239210 - Effects of Ondansetron in Obsessive-compulsive and Tic Disorders | Biotech Hunter | Biotech Hunter